; (F) formulary management and oversight; and (G) other subjects relevant to patients and other interested parties. (3) Program review Based on the recommendations discussed during any patient-focused listening sessions convened under paragraph (1), the Secretary shall conduct a review of relevant regulatory and sub-regulatory requirements under this part and shall consider, as appropriate, potential regulatory or sub-regulatory changes to address issues raised during such sessions. .